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Abstract
Background: Molecular analysis of circulating tumour DNA (ctDNA) is becoming increasingly important in clinical
treatment decisions. A pilot External Quality Assessment (EQA) scheme for ctDNA analysis was organized by four
European EQA providers under the umbrella organization IQN Path, in order to investigate the feasibility of delivering
an EQA to assess the detection of clinically relevant variants in plasma circulating cell-free DNA (cfDNA) and to analyze
reporting formats.
Methods: Thirty-two experienced laboratories received 5 samples for EGFR mutation analysis and/or 5 samples for KRAS
and NRAS mutation analysis. Samples were artificially manufactured to contain 3 mL of human plasma with 20 ng/mL of
fragmented ctDNA and variants at allelic frequencies of 1 and 5%.
Results: The scheme error rate was 20.1%. Higher error rates were observed for RAS testing when compared to EGFR
analysis, for allelic frequencies of 1% compared to 5%, and for cases including 2 different variants. The reports over-
interpreted wild-type results and frequently failed to comment on the amount of cfDNA extracted.
Conclusions: The pilot scheme demonstrated the feasibility of delivering a ctDNA EQA scheme and the need for such a
scheme due to high error rates in detecting low frequency clinically relevant variants. Recommendations to improve
reporting of cfDNA are provided.
Keywords: KRAS, NRAS, EGFR, Mutation testing, ctDNA, cfDNA, Lung cancer, Colorectal cancer
Background
In the last decade, the analysis of predictive biomarkers
has become an essential step in the optimisation of
therapy for cancer patients [1, 2] In routine practice,
tumour-specific mutation testing entails the analysis of
DNA extracted from tumour tissue which is harvested
from resections or biopsies. However, tumour tissue
sampling is often difficult, especially in patients with
advanced disease. In some cases, the tumour sample can
yield insufficient DNA for molecular analysis. This is
particularly evident in non-small-cell lung cancer
(NSCLC) patients, where in approximately 30% of
patients a tissue sample is not available for epidermal
growth factor receptor (EGFR) mutation analysis, either
at diagnosis or as the disease progresses [3]. In these
cases, the analysis of circulating cell-free (cfDNA)
derived from plasma has been proposed as an alternative
method for mutation testing [4, 5].
Plasma-derived cfDNA contains both circulating
tumour DNA (ctDNA) and nucleic acids released by
normal dividing cells. The mechanism by which tumour
cells release ctDNA into the blood is not fully known. It
is thought to involve mechanisms such as apoptosis and
necrosis, as suggested by the specific fragmentation
pattern of ctDNA (+/− 160 base pairs) which in turn is
suggestive of a nuclease-dependent degradation [6, 7]. It
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has also been proposed that tumour cells may secrete
DNA fragments through vesicles [3].
The advantage of cfDNA testing is that it is minimally
invasive and avoids incomplete or variable results arising
from tumour heterogeneity [8]. It may also be used to
monitor tumour progression [4, 5]. Many studies have
demonstrated the effectiveness of assessing tumour-spe-
cific alterations by testing plasma cfDNA. This evidence
led the European Medicine Agency to approve the use
of plasma to detect EGFR mutations in the plasma of pa-
tients with advanced NSCLC, when adequate tissue is
not available [9–11].
In patients with metastasized colorectal cancer (CRC),
cfDNA testing for Kirsten rat sarcoma viral oncogene
homolog (KRAS) and neuroblastoma rat sarcoma viral
oncogene homolog (NRAS) mutations also holds prog-
nostic value [12]. Consequently, numerous diagnostic
tools for the detection of EGFR, KRAS, NRAS and BRAF
mutations in cfDNA have recently become available.
Subsequently the role of cfDNA has moved from use in
diagnostic research to becoming a relevant testing
matrix in patients with solid tumours [13]. However, the
introduction of this novel methodology into clinical
practice can be challenging for many laboratories. For
instance, the standardization of testing procedures is
complex, ranging from plasma collection, cfDNA extrac-
tion and cfDNA mutation analysis, to result interpret-
ation. In addition, the analysis must be sufficiently
sensitive to identify rare mutant molecules in a back-
ground of wild-type DNA at range of 0.1–1%. Currently,
clinical applications of cfDNA are focused on the identi-
fication of primary mutations in pretreatment samples
and the subsequent detection of resistant mutations
upon progression in longitudinal samples, which inform
treatment decisions. However, the potential uses are nu-
merous and could include tumour monitoring and early
tumour diagnosis [4].
The objectives of this External Quality Assessment
(EQA) pilot scheme were to (i) investigate the feasibility
of designing and delivering a technically challenging
EQA (ii) evaluate and compare the ability of laboratories
to detect cfDNA in plasma samples (iii) evaluate which
extraction methodologies and testing method strategies
were used and (iv) to assess the reporting of ctDNA test-
ing results. For this purpose, four European EQA pro-
viders (Associazione Italiana di Oncologia Medica –
AIOM, European Molecular Genetics Quality Network -
EMQN, European Society of Pathology – ESP, United
Kingdom National External Quality Assessment Service
(UK NEQAS) for Molecular Genetics under the um-
brella organization the International Quality Network
for Pathology (IQN Path) [14], organised a pilot ctDNA
EQA scheme. In this paper, we present the results of this
scheme for the analysis of cfDNA for clinically relevant
mutations as well as provide recommendations for
reporting.
Methods
EQA scheme design
The pilot EQA was developed in 2016 and delivered to
participants during 2017 as a collaboration between the
four EQA providers. It was co-ordinated under the banner
of an IQN Path working group, with additional expertise
provided by scientific advisors. The pilot was carried out
according to the requirements of the International Stand-
ard for Conformity assessment of proficiency testing ISO
17043 [15] to ensure a robust audit trail was associated
with its design, development and implementation.
Thirty-two participant laboratories (eight from each
EQA provider) were chosen from a pool of 167 potential
candidates who completed a selection survey [13]. Selec-
tion criteria included technology available (to ensure
material suitability for a range of different technologies),
clinical diagnostic workload (to ensure inclusion of la-
boratories delivering a clinical ctDNA testing service),
global location (to assess sample stability during trans-
portation) and testing for EGFR and/or RAS genes (to
ensure relevance to current clinical practice).
The pilot EQA scheme consisted of a set of eight sam-
ples containing mutations in the EGFR, KRAS or NRAS
genes, in addition to two wild-type samples. The samples
were shipped on dry ice (BioCair, Cambridge, United
Kingdom) to each participant laboratory and the transit
temperatures were monitored. Participants were asked
to test the samples for the isolation of cfDNA and subse-
quent genotyping according to their established routine
procedures. A central system for electronic result collec-
tion was set up in accordance with ISO 17043 [15] to
which the validating laboratories as well as the partici-
pants were able to submit their genotyping results and
background information on the testing process.
Participating laboratories were asked to submit inter-
pretative diagnostic reports for assessment via their EQA
provider. All results provided within the submitted reports
were assessed independently by at least two IQN Path
working group members against the same pre-defined
scoring criteria, harmonized between the four EQA pro-
viders (Table 1). Samples A-E versus samples F-J were
scored, for RAS and EGFR testing, respectively. For every
case, a maximum of 2 points was awarded and points
were deducted depending on the type of error made
(Table 1). This yielded a total genotyping score on 20
points for participants to both RAS and EGFR analysis,
and a total score on 10 points for participants to one of
both sample sets. For every case, an average genotyping
score was calculated on the maximum of 2 points across
all participants. Each participant laboratory received an
individual feedback report (Additional file 1), as well as a
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general report summarizing the expected results, scheme
statistics and final results.
EQA sample preparation and validation
A panel of 10 artificial samples, 5 samples each for colo-
rectal (Cases A-E) and lung (Cases F-J) cancer testing,
were manufactured by and purchased from Horizon Dis-
covery Ltd. (Cambridge, United Kingdom) according to
a specification provided by the IQN Path working group.
These included common, clinically relevant mutations in
the KRAS, NRAS and EGFR genes with variant allelic
frequencies of 1% or 5%, and also incorporated two
wild-type samples (Table 1). Each sample comprised
3 mL human plasma containing 20 ng/mL ctDNA, frag-
mented to 150 base pairs in length.
Samples were created by reviving and expanding char-
acterised cell lines of which gDNA pellets were created.
DNA was extracted from the pellets, fragmented to 150
base pairs (+/− 10%), and diluted to the target concen-
tration. The obtained cfDNA was spiked into normal hu-
man donor plasma, for which a copy detection analysis
was performed on the background genes. The DNA was
extracted once more and a final quality check was per-
formed by estimating the fractional abundance.
Prior to their use in the pilot EQA scheme, each sample
was characterised and validated by five reference laborator-
ies, using a range of methodologies (Table 2) to verify
sample performance in the pre-analytical and analytical
processes, as well as to confirm that the expected genotype
met the material specification provided by the IQN Path
working group, and to ensure that the material reflected
routine clinical samples in the hands of multiple laborator-
ies. Extraction and analysis methods were selected based on
the available methodologies that were validated for EGFR
and/or RAS analysis in the reference laboratories, with the
purpose of reflecting at least one method for every tech-
nique type, namely next-generation sequencing (NGS),
droplet digital PCR (ddPCR), commercial kit, and beads,
emulsification, amplification, and magnetics (BEAMing).
Optionally, a second laboratory validated the samples using
the same methodology if available. The analysed results
from the validation trial were collectively reviewed by the
IQN Path working group before the materials were released
for use in the pilot EQA scheme.
Computational and statistical analysis
EQA participant and validation data from the pilot EQA
scheme were analyzed using Microsoft Excel 2013
(Microsoft, Redmond, WA, United States of America).
The overall error rate was calculated by dividing the
total number of false-positive and false-negative results
over the total number of genotypes reported by the par-
ticipants. False-positive or false-negative results for
which the treatment outcome would be affected were
considered as critical errors when calculating the rate.
Incorrect variants at the same codon were not classified
as critical genotyping errors. False-negative results for
which the sample genotype was not included in the
Table 2 Overview of error rates per case for different methods for cfDNA extraction and variant analysis during validation
cfDNA
extraction method
Cobas cfDNA
sample preparation
kit (Roche)
QIAamp Circulating Nucleic Acid Kit (Qiagen)
Variant analysis
method
Cobas® EGFR Mutation
Test v2 (Roche)
Capture
SureSelect (Agilent),
MiSeq (Illumina)
QX200 Droplet
Digital PCR
System
(Bio-rad)
Ampliseq 50 gene
hotspot panel, Ion
Proton
(LifeTechnologies)
Therascreen®
EGFR Plasma
RGQ PCR Kit
(Qiagen)
OncoBEAM®
RAS CRC IVD KIT
(Sysmex-Inostics)
Reference
laboratory code
1, 2 2 3°, 4 4 5 5 1–5
Sample # errors/# genotypes analyzed (error rate in %)
A / 1/1 (100.0%) 0/2 (0.0%) 0/1 (0.0%) / 0/1 (0.0%) 1/5 (20.0%)
B / 1/1 (100.0%) 0/2 (0.0%) 1/1 (100.0%) / 0/1 (0.0%) 2/5 (40.0%)
C / 1/1 (100.0%) 0/1 (0.0%) 0/1 (0.0%) / 0/1 (0.0%) 1/4 (25.0%)
D / 1/1 (100.0%) 1/1 (100.0%) 1/1 (100.0%) / 0/1 (0.0%) 3/4 (75.0%)
E / 0/1 (0.0%) 0/2 (0.0%) 0/1 (0.0%) / 0/1 (0.0%) 0/5 (0.0%)
F 0/2 (0.0%) 1/1 (100.0%) 0/2 (0.0%) 0/1 (0.0%) 0/1 (0.0%) / 1/7 (14.3%)
G 0/2 (0.0%) 1/1 (100.0%) 0/2 (0.0%) 0/1 (0.0%) 0/1 (0.0%) / 1/7 (14.3%)
H 0/2 (0.0%) 1/1 (100.0%) 0/2 (0.0%) 1/1 (100.0%) 0/1 (0.0%) / 2/7 (28.6%)
I 1/2 (50.0%) 1/1 (100.0%) 1/2 (50.0%) 1/1 (100.0%) 0/1 (0.0%) / 4/7 (57.1%)
J 0/2 (0.0%) 0/1 (0.0%) 0/2 (0.0%) 0/1 (0.0%) 0/1 (0.0%) / 0/7 (0.0%)
A-J 1/10 (10.0%) 8/10 (80.0%) 2/18 (11.1%) 4/10 (40.0%) 0/5 (0.0%) 0/5 (0.0%) 15/58 (25.9%)
/, Sample not tested because gene not included in validated methodology. °Reference laboratory n°3 did not test NRAS status. Reference sequence
at time of scoring: EGFR: NM_005228.4 or LRG_304t1; KRAS: NM_033360.3 or NM_004985.4; NRAS: NM_002524.4 or LRG_92t1
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methodology, or where it was below the stated limit of
detection (LOD), were included in error rates because
laboratories offering diagnostic mutational analysis on
cfDNA should test for the selected clinically relevant
variants. Technical failures were excluded from the total
number of genotypes. Participants that did not subscribe
and thus did not receive either the 5 EGFR or 5 RAS
samples were also not scored for those samples. Statis-
tical difference between reported variant allele frequen-
cies (VAFs) were compared between techniques using a
Mann Whitney U (MWU) test, for both the 1% and 5%
variants, with a significance level of α = 0.05.
Results
No technical failures were observed by the reference
laboratories using two commonly used cfDNA extrac-
tion methods and six different mutation test methods
(Table 2).
Fifteen (25.9%) false-positive or false-negative results
were reported for a total of 58 analyzed genotypes
(Table 2). On average, more false-negative results were
reported for the RAS samples when compared to EGFR.
The Capture SureSelect (Agilent) panel on the MiSeq
(Illumina) sequencer was not able to detect any of the
included EGFR or RAS variants in the plasma samples.
In contrast, the Ion Ampliseq 50 gene hotspot panel on
an Ion Proton (Life Technologies) was able to detect
the single deletions in exon 19 of EGFR and RAS vari-
ants included at 5%. However, in the samples with
EGFR p.(L858R) and p.(T790 M) (cases H, I), 6/14 tests
were not able to detect at least one of the two muta-
tions. No false-positive results were reported in the two
wild-type samples or in any of the other cases as an
additional variant.
The validation of these samples revealed that different
ctDNA-based detection methods are able to correctly
detect the genotype in 1% and 5% samples with a low
false-positive rate. Our validation procedure also re-
vealed that for less sensitive analytical methods, the 1%
samples can be challenging. As the VAFs were still rela-
tively high, we decided to perform the pilot EQA for
KRAS/NRAS and EGFR using the five samples for the
EGFR and KRAS/NRAS scheme. To additionally assess
the quality of the samples, DNA yield was measured by
each of the five reference laboratories using the QIAamp
Circulating Nucleic Acid Kit (Qiagen), and resulted in
an average of 0.66 μg/mL (min. 0.11 μg/mL, max.
4.63 μg/mL). Assessing the DNA yield is not part of the
integrated workflow for cobas extraction and analysis.
In total, 32 laboratories from 16 countries participated
in the pilot EQA scheme (Fig. 1). Thirty-one (97%) labora-
tories submitted an electronic datasheet providing details
on their cfDNA extraction, analysis methods, and a list of
variants tested. One of the 31 laboratories did not submit
written reports, therefore their genotyping results were
only scored on the entries from the electronic table. In
total, 23 participants tested the samples for KRAS/NRAS
analysis, and 31 participants for EGFR analysis. Three of
23 participants receiving the KRAS/NRAS mutation sam-
ples did not perform any NRAS mutation testing but did
perform KRAS analysis in these samples.
Of all 31 participants, six different cfDNA extraction
methods were used (Table 3). The majority of the partici-
pants (55%) used the QIAamp Circulating Nucleic Acid
Kit (Qiagen) for cfDNA extraction. Only one laboratory
used an automated cfDNA extraction method (Promega
Maxwell® RSC ccfDNA Plasma Kit). For KRAS, NRAS and
EGFR mutation analysis, the most frequently used
detection methodologies were NGS (39%) and droplet
digital polymerase chain reaction (ddPCR) (23%) (Table 3,
Additional file 2: Table S2). A combination of platforms
and panels was applied, although the largest fraction of
NGS users analyzed the plasma samples with the PGM
Ion Torrent (Life Technologies).
Fig. 1 Overview of the participating countries to the pilot EQA scheme. United Kingdom: One laboratory received both RAS (KRAS/NRAS) and
EGFR samples but did not submit results for KRAS/NRAS as they were in the process of validation. In total, 23 participants tested the samples for
KRAS/NRAS analysis, and 31 participants for EGFR analysis
Keppens et al. BMC Cancer  (2018) 18:804 Page 6 of 11
In total, 3 (1.1%) technical failures by 3 different partici-
pants, were observed from a total of 270 reported genotypes.
One technical failure was classed as a partial failure as only
the NRAS gene analysis failed to provde a reportable result.
Hence the reported genotypes for this case were included
for KRAS analysis, yielding a total of 268 analyzed samples.
The reasons reported for technical failures included NGS
read depth too low (Case A), problem with DNA extraction
(Case G), or a defective cartridge for the partial failure
(NRAS only, Case B). The overall scheme error rate was 54
(20.1%) on the total of 268 samples. Most errors were
observed for KRAS/NRAS mutation testing (34/114, 29.8%
samples, cases A-D), whereas error rates for EGFR analysis
were lower (20/154 samples, 13.0%, cases F-I).
Combining the two samples containing a variant at a
frequency of 5% and the two with a variant of 1%, yielded
a total error rate of 15/45 (33.3%) and 19/46 (41.3%) com-
pared to 4/61 (6.6%) and 15/62 (24.2%) for RAS and EGFR
testing respectively. Sample I was withdrawn from the
EQA scheme assessment but for information purposes,
for EGFR analysis, the majority of the genotyping errors
(13 of 20 errors) were observed for this sample I (Table 1)
as only 18 out of 31 laboratories (58%) reported the pres-
ence of both the EGFR mutations at a frequency of 1%.
Only one false-positive result (1/54 samples, 1.9%) was
observed in the two wild-type samples (cases E and J). In
the other four cases, 4/91 false-positive results were
obtained for RAS, and 1/123 for EGFR analysis (Table 1).
Genotyping errors with no impact on therapeutic deci-
sions were also observed but not included in the calcula-
tion of the error rate e.g. the detection of an incorrect
KRAS/NRAS nucleotide variant resulting in a change
within the same codon, or the incorrect annotation of the
EGFR exon 19 deletion by NGS users (Table 1). Taking
into account the number of laboratories using a specific
methodology, the method specific error rate over all sam-
ples was the highest for NGS (23%) compared to ddPCR
(15%) and commercial kits (15%) (data not shown).
Participants were not asked specifically to report VAFs
so only a small number of laboratories provided this
information. The mean VAF was calculated for the cases
containing a mutation, for which the mutation was
correctly detected (Fig. 2). Average VAFs closely resem-
bled the expected frequencies for 5% and 1%, but a very
broad range was observed. The average VAF for the cases
with variants at 5% was 4.0% (number of genotypes = 82,
minimum VAF 0.6%, maximum VAF 13.0%). For variants
at 1%, the estimated VAFs were 1.4% (number of geno-
types = 57, minimum VAF 0.3%, maximum VAF 10.4%).
(Fig. 2). Average VAFs were closer to the expected VAF
for ddPCR when compared to NGS, but not significant
for either the 1% cases (Mann-Whitney-U, p = 0.289, n =
11 ddPCR and n = 34 NGS) or the 5% cases (Mann-Whit-
ney-U, p = 0.294, n = 17 ddPCR and n = 51 NGS).
The content of the reports varied between laboratories.
The most important observation was that several labora-
tories over-interpreted the absence of a relevant mutation
without providing information on quality control (QC)
metrics. It is important to state if the input DNA and
LOD were appropriate to reliably interpret the results as
negative. Without this information, clinical interpretation
may be incorrect. For example, a negative result could be
Table 3 Overview of the cfDNA extraction and variant analysis methods methods used by the participants
# participants to KRAS analysis
(%) (n = 23)
# participants to NRAS analysis
(%) (n = 20)
# participants to EGFR analysis
(%) (n = 31)
cfDNA extraction method
QIAamp Circulating Nucleic AcidKit (Qiagen) 14 (60.9) 13 (65.0) 17 (54.8)
Cobas cfDNA Sample Preparation Kit (Roche) 4 (17.4) 3 (15.0) 8 (25.8)
MagMAX Cell-Free DNA Isolation Kit
(Thermo Fisher Scientific)
3 (13.0) 3 (15.0) 3 (9.7)
Maxwell® RSC ccfDNA Plasma Kit (Promega) 1 (4.3) 0 (0.0) 1 (3.2)
Nucleospin Plasma XS (Macherey-Nagel) 1 (4.3) 1 (5.0) 1 (3.2)
QIAamp DSP DNA Blood Mini Kit (Qiagen)
version 2
0 (0.0) 0 (0.0) 1 (3.2)
Variant analysis method
NGS 13 (56.5) 13 (65.0) 12 (38.7)
Commercial Kit 4 (17.4) 3 (15.0) 11 (35.5)
LDT 1 (4.3) 0 (0.0) 1 (3.2)
BEAMing 1 (4.3) 1 (5.0) 0 (0.0)
ddPCR 4 (17.4) 3 (15.0) 7 (22.6)
The LDT consisted of a 5’nuclease polymerase-chain reaction (Taqman) with peptide nucleic acid probe. For a detailed breakdown of the used methods see
Additional file 2: Table S2. Abbreviations: BEAMing Beads, emulsification, amplification, and magnetics, ddPCR Droplet digital polymerase chain reaction, LDT
Labroratory-developed test, NGS Next-generation sequencing
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interpretated as (i) the absence of a mutation indicating
that the patient should receive anti-EGFR antibody ther-
apy (in the case of CRC and RAS mutations) or that (ii)
the patient would be unlikely to benefit from EGFR-tyro-
sine kinase Inhibitors (in the case of NSCLC and EGFR
mutation). In addition, there was no standardisation in the
reporting of the amount of cfDNA extracted, or the LOD.
Only a small number of laboratories related the amount
of input cfDNA to the assay sensitivity. Variation was also
observed for several other elements, including the correct
use of Human Genome Variation Society (HGVS) nomen-
clature [16, 17], reporting of reference sequences [18], and
the specification of analysis limits of the methodology.
Discussion
Plasma cfDNA analysis is emerging as a valuable tool to
complement resected solid tumour or biopsy material in
targeted treatment decisions. Many of the participating
laboratories have been performing ctDNA analysis for
some time. As there are no current EQAs for testing
clinically relevant mutations in plasma, there is an ur-
gent need for well-designed EQA schemes to provide
education and benchmarking in order to permit imple-
mentation in an accurate, highly qualitative manner [13].
The acquisition and validation of artificial material for
this pilot ctDNA molecular testing EQA was harmonized
between several EQA schemes. The main goal was to
harmonize the minimal requirements for the implementa-
tion of a ctDNA EQA scheme, in order to score the
laboratories’ analytical performance and reporting, and
eventually to serve as guidance for the organization of
future large-scale EQA schemes. Secondly, harmonization
between the four European EQA providers aimed to in-
crease efficiency, and reduce the cost of delivery and speed
of access to EQA.
This pilot EQA scheme demonstrated the feasibility of
designing and delivering a technically challenging EQA. It
also demonstrated sample stability during in-house distri-
bution, preparation and transportation, which enabled the
testing laboratory to produce a reportable result.
Technical failures were reported for only 3/270 (1.1%)
of samples (Table 1) and there were none reported during
validation (Table 2). However, a high rate of genotype er-
rors was observed by the participants (20.1%). Prior to dis-
tribution, in the validation process we observed that the
samples with 1% VAF and cases with the two relevant
EGFR variants were challenging. This was reflected in FN
rate (Table 1). Although during validation only six differ-
ent detection methods were applied (including two differ-
ent NGS assays), the results indicated that the analytical
sensitivity of the methods is important and could be an
explanation for the poorer performance of NGS.
In the pilot scheme the participants used a wide range
of detection methods, and selected arbitrary cut-offs as a
LOD for their assays (when indicated). Our analysis
revealed that the highest error rates (false-negative rates)
occurred for less sensitive techniques for ctDNA analysis,
in concordance with the validation testing and the recent
German pilot scheme [19]. Interestingly, when partici-
pants were separated into those using commercially
available panels (n = 8 for both EGFR and RAS analysis)
and those using in-house primers or panels (n = 5 for RAS
and n = 4 for EGFR analysis), the commercial NGS
methods showed excellent scores whereas the latter dem-
onstrated a significantly higher error rate. These findings
underline the need for robust validation of in-house NGS
approaches for cfDNA testing.
For the samples which yielded a reportable result, more
errors were observed for RAS analysis when compared to
EGFR analysis. EGFRmutation testing in cfDNA is already
widely implemented in clinical practice, whereas RAS
plasma testing is still an experimental procedure in many
centers, a fact which may account for the error rates. In
addition, more participants are using commercial, targeted
Fig. 2 Average variant allele frequencies by the pilot scheme participants and reference laboratories. Case E and J were not included since they
were wild-type. Only the variant allele frequencies of correctly identified variants were taken into account. Min: minimum variant allele frequency
reported, max: maximum variant allele frequency reported
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assays for EGFR detection compared to NGS for RAS ana-
lysis (Table 3). Non-NGS based methods are known to
have a greater sensitivity and require less complicated
bio-informatics. Despite the high error rate for case D, this
sample was retained in the assessment as errors seemed to
be related to a poorer performance of NGS, with more
participants using this technology compared to EGFR ana-
lysis for case I. As recommended previously [19], we eval-
uated the estimated VAFs compared to the expected
outcome, in order to assess scheme quality (Fig. 2). We
found that average VAFs closely resembled the expected
frequencies for 5 and 1%, especially for ddPCR when com-
pared to NGS, although results were not significant as a
broad range of VAFs were reported.
Many genotyping errors were observed for the two
cases which included both an activating and a resistance
EGFR variant: the majority of participants did not detect
the p.(T790M) variant, especially at a VAF of 1%. Since
the majority of EGFR mutations detected in the ctDNA
of NSCLC patients are detected at < 5% allelic frequency,
this would mean that a significant fraction of patients
would not have received targeted treatment as result of
these tests. For metastatic colorectal cancer, the likely
consequence of a false negative result is that a patient
inappropriately receives anti-EGFR treatment. The over-
all scheme error rate was higher than that observed in
the German ctDNA EQA scheme [19]. However, we in-
cluded variants at a VAF of 1% and 5% to resemble pa-
tient material as closely as possible, rather than at 5%
and 10% as previously reported [19]. Furthermore, with
the majority of laboratories using less sensitive techniques
(Table 3), a fraction of the observed false-negative results
occurred because the variant was included at a frequency
below the LOD (Table 1). This observation highlights the
issue of reporting mutations at low levels when the clinical
significance is not known. Taking into account only the
true false-negative results, the scheme error rates would
be lower and therapy decision making would not always
be compromised.
However, the error rates should be interpreted with
some caution especially in assays used by a small num-
ber of participants, such as BEAMing and for some la-
boratory-developed tests (LDTs) (Table 3). To be able to
draw firm conclusions on different cfDNA detection as-
says, an EQA with more than 500 participants is needed
on a regular basis.
The high number of genotyping errors reported by this
group of participants potentially indicates that the artifi-
cial material provided does not perform the same way as
clinical samples. The difficulties in the implementation
of this new methodology to clinical practice and the
enormous variation in methods to process plasma, ex-
tract cfDNA and detect ctDNA, all compounded by a
lack of guidelines, go some way to explain the observed
variations. Additionally, some laboratories reported diffi-
culties in extracting sufficient cfDNA material or specif-
ically reported a reduced assay sensitivity due to the
limitations of the supplied material.
Finding sufficient plasma samples from patients with
known ctDNA mutations to use in EQA is challenging,
mainly due to the amount of plasma required. For this
reason, EQA providers are limited to using artificial
EQA samples. In this pilot EQA scheme, cell-line de-
rived DNA was spiked into normal plasma, which has
the advantage that plasma quantities can be boosted.
However, it also runs the risk that different background
DNA levels could be present. The fact that cell-line
DNA was used instead of plasmids has the advantage of
allowing stoichiometric and unbiased dilutions, including
QC of the dilution steps, as well as permitting fragmenta-
tion of the DNA to resemble the structure of ctDNA ob-
served in patients. Alternatively, artificial plasma may be
used [20]. However, plasmid DNA may not be an ideal
control sample as it does not represent the true genomic
complexity of human tumour samples [20].
Besides the analytical assessment, EQA also assesses the
post-analytical phase. The pilot EQA scheme results stress
the need for standardization of several elements. Although
reporting has been shown to improve across subsequent
EQA schemes for formalin-fixed paraffin-embedded tissue
for different EQA providers [21, 22], plasma cfDNA test-
ing as a new technology requires the inclusion of specific
content in addition to some general elements, such as the
use of standardized HGVS nomenclature [16, 17] and ref-
erence sequences [18]. However, best practice guidance
for cfDNA reporting is currently not available.
More specifically, this pilot EQA highlighted the need to
report wild-type results, and to provide a clinical interpret-
ation when no mutation was detected. Because, even in
samples where a mutation is present, there are several
reasons why a wild-type result might have been obtained.
At certain stages of cancer progression, the amount of
ctDNA may be too low to detect, as there is no shedding
of tumour DNA. For CRC and NSCLC, a positive associ-
ation has been described between the tumour volume
and the presence of ctDNA [6, 23, 24]. In addition,
whether the disease is localized rather than metastatic
also significantly affects the ctDNA content in gastro-in-
testinal stromal tumours [25]. In only 70% of NSCLC
cases, the EGFR mutation detected in the biopsy is also
detected in plasma at the base-line [26] and at progres-
sion while on therapy [3]. Therefore, in the case of nega-
tive results with sufficient cfDNA input, it is important
to obtain a tissue biopsy and when this is not possible,
plasma testing should be repeated on a new sample. We
also recommend not to use the terms ‘positive/negative’
to describe the mutation status in reports, as this can be
misinterpreted: rather, ‘mutation detected/mutation not
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detected’ terminology should be employed. Secondly, a
false-negative result can arise if the sensitivity and LOD
of the assay is too low, and to date assay sensitivities
vary between < 0.1 - < 1% [4]. Therefore, data sensitivity
of mutation detection and LOD should be recorded in
the report. In the pilot scheme there was a high diversity
among laboratories regarding the reporting of sensitiv-
ities, which were expressed in either as copies/mL or as
allelic frequency (percentage). For both options it is rec-
ommended that the amount of cfDNA extracted for a
sample is included and that this should be related to the
assay sensitivity because if the input of the total amount
of cfDNA is too low, the test will also be negative.
Thirdly, if the assay does not cover all the relevant vari-
ants and regions, a mutation might be missed. There-
fore, a detailed inclusion of the list of variants, codons
or exons tested should be present.
It is important to report the QC metrics of the test
performance. Several laboratories reported an incorrect
sequence of the deletions in EGFR exon 19. While this
error will not compromise patients’ treatment, it high-
lights the need for improvements of bioinformatics
workflow. A false-negative result could also arise due to
haemolysis during collection and processing of blood
plasma, diluting the mutant DNA to non-detectable
levels [3, 27]. Therefore it is clear that ctDNA testing re-
quires additional guidelines for preanalytical processing.
The utility of circulating biomarkers in the molecular
analysis of solid tumours is an exciting new mutation detec-
tion tool with many potential applications [28]. However,
the highly sensitive testing technology and the handling of
appropriate samples is challenging. Standardization is
essential to ensure that patients receive the correct results,
and so that appropriate treatment is delivered. The
provision of EQA is also essential to reassure testing labora-
tories of the standard of their cfDNA testing service.
Conclusions
As with all EQA schemes, laboratories are encouraged to
review their EQA results to ensure no errors have occurred.
Errors can impact on the clinical testing service by follow-
ing up on sub-optimal performance. Based on the findings
of this pilot EQA scheme, the need for EQA schemes for
all laboratories providing a cfDNA mutation testing service
for lung and colorectal cancer has been identified. With this
in mind, a second EQA round will be organized in 2018,
which will be open to all laboratories from all countries.
Additional files
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Additional file 2: Table S2. Description: Detailed overview of the
mutation detection techniques used by the EQA participants. (XLSX 12 kb)
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